Evidence map›Paper›PMID 32560474›Full record

ArticleNanomaterials (Basel, Switzerland)2020

Gold Nanoparticle-Assisted Virus Formation by Means of the Delivery of an Oncolytic Adenovirus Genome.

Luis Sendra, Antonio Miguel, M Carmen Navarro-Plaza, María José Herrero, José de la Higuera, Consuelo Cháfer-Pericás, Elena Aznar, M Dolores Marcos, Ramón Martínez-Máñez, Luis Alfonso Rojas and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.International journal of molecular sciences · 2024
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Luis SendraGene Therapy Group, Department of Pharmacology, Faculty of Medicine, Universitat de València, Av Blasco Ibáñez 15, 46010 València, Spain.
Antonio MiguelGene Therapy Group, Department of Pharmacology, Faculty of Medicine, Universitat de València, Av Blasco Ibáñez 15, 46010 València, Spain.
M Carmen Navarro-PlazaGene Therapy Group, Department of Pharmacology, Faculty of Medicine, Universitat de València, Av Blasco Ibáñez 15, 46010 València, Spain.
María José HerreroGene Therapy Group, Department of Pharmacology, Faculty of Medicine, Universitat de València, Av Blasco Ibáñez 15, 46010 València, Spain.
José de la HigueraGene Therapy Group, Department of Pharmacology, Faculty of Medicine, Universitat de València, Av Blasco Ibáñez 15, 46010 València, Spain.
Consuelo Cháfer-PericásInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico, Universitat Politècnica de València, Universitat de València, Camino de Vera s/n, 46022 Valencia, Spain.
Elena AznarInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico, Universitat Politècnica de València, Universitat de València, Camino de Vera s/n, 46022 Valencia, Spain.
M Dolores MarcosInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico, Universitat Politècnica de València, Universitat de València, Camino de Vera s/n, 46022 Valencia, Spain.
Ramón Martínez-MáñezInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico, Universitat Politècnica de València, Universitat de València, Camino de Vera s/n, 46022 Valencia, Spain.
Luis Alfonso RojasCatalan Institute of Oncology-IDIBELL, Av Gran Via 199-203, 08908 Barcelona, L'Hospitalet de Llobregat, Spain.
Ramón AlemanyCatalan Institute of Oncology-IDIBELL, Av Gran Via 199-203, 08908 Barcelona, L'Hospitalet de Llobregat, Spain.
Salvador F AliñoGene Therapy Group, Department of Pharmacology, Faculty of Medicine, Universitat de València, Av Blasco Ibáñez 15, 46010 València, Spain.
Universitat de València · ESInstitut d'Investigació Biomédica de Bellvitge · ES

Funding

Asociación Pablo Ugarte Ayuda a la investigacionEuropean Regional Development Fund VLC-CAMPUSUniversitat de València Ayuda a la Investigación
6 · The paper itself

Abstract

Oncolytic adenoviruses are a therapeutic alternative to treat cancer based on their ability to replicate selectively in tumor cells. However, their use is limited mainly by the neutralizing antibody (Nab) immune response that prevents repeated dosing. An alternative to facilitate the DNA access to the tumor even in the presence of anti-viral Nabs could be gold nanoparticles able to transfer DNA molecules. However, the ability of these nanoparticles to carry large DNA molecules, such as an oncolytic adenovirus genome, has not been studied. In this work, gold nanoparticles were functionalized with different amounts of polyethylenimine to transfer in a safe and efficient manner a large oncolytic virus genome. Their transfer efficacy and final effect of the oncolytic virus in cancer cells are studied. For each synthesized nanoparticle, (a) DNA loading capacity, (b) complex size, (c) DNA protection ability, (d) transfection efficacy and (e) cytotoxic effect were studied. We observed that small gold nanoparticles (70-80 nm in diameter) protected DNA against nucleases and were able to transfect the ICOVIR-15 oncolytic virus genome encoded in pLR1 plasmid. In the present work, efficient transgene RNA expression, luciferase activity and viral cytopathic effect on cancer cells are reported. These results suggest gold nanoparticles to be an efficient and safe vector for oncolytic adenovirus genome transfer.

Indexed as

cancerdeliverygene therapygold nanoparticlesnon-viral vectorsoncolytic virusvirotherapy

Identifiers

PMID32560474
PMCPMC7353451
OpenAlexW3035776375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.